Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014)
Insmed (INSM) posted Non-Current Deffered Revenue of $118000.0 for Q4 2014, down 36.22% on a QoQ basis from $185000.0 in Q3 2014, and down 68.95% year-over-year from $380000.0 in Q4 2013.
Analysis
Insmed (INSM) Non-Current Deffered Revenue (2012 - 2014) Analysis & Trends
Insmed has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $118000.0 in Q4 2014.
- On a quarterly basis, Non-Current Deffered Revenue fell 68.95% year-over-year to $118000.0 in Q4 2014; TTM through Dec 2014 was $118000.0, a 68.95% decrease from a year earlier, with the FY2014 full-year figure at $118000.0, down 68.95% from the prior year.
- Non-Current Deffered Revenue was $118000.0 for Q4 2014 at Insmed, down from $185000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $647000.0 in Q4 2012, with the low at $118000.0 in Q4 2014.
- Average Non-Current Deffered Revenue over 3 years is $382000.0, with a median of $380000.0 recorded in 2013.
- The sharpest annual moves came in 2013 and 2014: Non-Current Deffered Revenue sank 41.27% in 2013, then slumped 68.95% in 2014.
- Over 3 years, Non-Current Deffered Revenue stood at $647000.0 in 2012, then tumbled by 41.27% to $380000.0 in 2013, then plunged by 68.95% to $118000.0 in 2014.
- The last three Non-Current Deffered Revenue figures came in at $118000.0 (Q4 2014), $185000.0 (Q3 2014), and $250000.0 (Q2 2014), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 220.40 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 147.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2014 | 118,000.00 |
| Sep 30, 2014 | 185,000.00 |
| Jun 30, 2014 | 250,000.00 |
| Mar 31, 2014 | 315,000.00 |
| Dec 31, 2013 | 380,000.00 |
| Sep 30, 2013 | 449,000.00 |
| Jun 30, 2013 | 514,000.00 |
| Mar 31, 2013 | 580,000.00 |
| Dec 31, 2012 | 647,000.00 |